ESMO Interactive Guidelines vs EAU NMIBC Risk Calculator

The European Society for Medical Oncology (ESMO) guidelines are developed by experts. They are concise, practical and offer users treatment recommendations that are based on the latest scientific research. This application uses interactive tools to support decision making and help the user navigate the guidelines easily, so they can access the information they require quickly. Each guideline offers best practice recommendations for screening, diagnosis, staging, treatment and follow up. The ESMO Interactive Guidelines application ensures the user has the highest standard of information at their figure tips. A variety of interactive treatment algorithms, tables, calculators and scores can be utilised to assist the treating doctor. The user can also perform key word searches, bookmark useful pages, add notes and email pages to colleagues or patients. The app features news and push notifications. Disclaimer: The app is intended to assist healthcare professionals and allied healthcare professionals as an educational tool to provide information that may support them in providing care to patients. Patients or other community members using this app shall do so only after consultation with a health professional and shall not mistake these guidelines as professional medical advice. These guidelines must not substitute seeking professional medical and health advice from a health professional. These guidelines may not apply to all situations and shall be interpreted in the light of specific clinical situations and resource availability. It is up to every clinician to adapt these guidelines to local regulations and to each patient’s individual circumstances and needs. The app contains information obtained from authentic and highly regarded sources (http://www.esmo.org). Although every effort has been made to ensure that treatment and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician.This application is updated regularly with more tumour types, guidelines and interactive tools.

This app estimates the probability of a Non–muscle Invasive Bladder Cancer (NMIBC) patient’s progression to MIBC after trans-urethral resection of bladder tumours (TURBT) and calculates their updated European Association of Urology (EAU) Prognostic Factor Risk Group. It Incorporates both the WHO 2004/2016 and WHO 1973 Grading Classification Systems and is based on the following publication: Sylvester RJ, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol (2021),https://doi.org/10.1016/j.eururo.2020.12.033 It is a tool that can be used to help inform treatment decisions, but it does not provide professional advice and it can never replace clinical expertise. Treatment decisions for individual patients should take into account not only clinical expertise, but also patient personal values and their preferences. This calculator has been developed by Ydeal for the EAU. Its developers and its distributors assume no responsibility for the accuracy of the results that are provided or for possible flaws in the system. Nor are they liable for special, direct, indirect or consequential damages, charges, claims, costs, demands, losses, fees or expenses of any nature or kind arising from use of the system. Comments, suggestions and any errors that are found should be sent to info@nmibc.net © European Association of Urology By using the system, the User agrees to these conditions and to abide by international copyright laws and all other applicable laws involving copyright.